ACAD
34.71
+0.99
+2.94%
AEMD
2.12
-0.13
-5.78%
APRI
1.16
-0.06
-4.92%
ARNA
1.39
+0.03
+2.21%
ATEC
1.98
+0.02
+1.02%
CNAT
7.52
-0.12
-1.57%
CRXM
0.2
0.00
0.00%
CYTX
1.06
-0.04
-3.64%
DXCM
74.94
+0.05
+0.07%
GNMK
12.855
+0.305
+2.430%
HALO
13.96
+0.57
+4.26%
ILMN
181.5
+1.3
+0.72%
INNV
0.093
-0.002
-2.0000%
INO
6.79
+0.26
+3.98%
ISCO
1.63
-0.02
-1.21%
ISIS
57.56
0.00
0.00%
LGND
108.9
+3.78
+3.60%
LPTN
2.93
0.00
0.00%
MBVX
2.08
+0.07
+3.48%
MEIP
1.56
0.00
0.00%
MNOV
5.57
+0.14
+2.58%
MRTX
4.6
+0.2
+4.55%
MSTX
0.135
-0.003
-2.0275%
NBIX
53.62
+1.84
+3.55%
NUVA
76.94
+0.59
+0.77%
ONCS
1.16
-0.01
-0.8546%
ONVO
2.78
+0.05
+1.83%
OREX
3.1
+0.12
+4.03%
OTIC
13.2
+0.7
+5.60%
QDEL
24.5
+1
+4.26%
RCPT
231.96
0.00
0.00%
RGLS
1.45
+0.05
+3.57%
RMD
70.94
+0.2
+0.28%
SPHS
2.6
-0.01
-0.38%
SRNE
1.9
+0.15
+8.57%
TROV
0.877
-0.003
-0.3070%
VICL
2.36
-0.01
-0.38%
VOLC
18
0.00
0.00%
ZGNX
10.8
+0.2
+1.89%
ACAD
34.71
+0.99
+2.94%
AEMD
2.12
-0.13
-5.78%
APRI
1.16
-0.06
-4.92%
ARNA
1.39
+0.03
+2.21%
ATEC
1.98
+0.02
+1.02%
CNAT
7.52
-0.12
-1.57%
CRXM
0.2
0.00
0.00%
CYTX
1.06
-0.04
-3.64%
DXCM
74.94
+0.05
+0.07%
GNMK
12.855
+0.305
+2.430%
HALO
13.96
+0.57
+4.26%
ILMN
181.5
+1.3
+0.72%
INNV
0.093
-0.002
-2.0000%
INO
6.79
+0.26
+3.98%
ISCO
1.63
-0.02
-1.21%
ISIS
57.56
0.00
0.00%
LGND
108.9
+3.78
+3.60%
LPTN
2.93
0.00
0.00%
MBVX
2.08
+0.07
+3.48%
MEIP
1.56
0.00
0.00%
MNOV
5.57
+0.14
+2.58%
MRTX
4.6
+0.2
+4.55%
MSTX
0.135
-0.003
-2.0275%
NBIX
53.62
+1.84
+3.55%
NUVA
76.94
+0.59
+0.77%
ONCS
1.16
-0.01
-0.8546%
ONVO
2.78
+0.05
+1.83%
OREX
3.1
+0.12
+4.03%
OTIC
13.2
+0.7
+5.60%
QDEL
24.5
+1
+4.26%
RCPT
231.96
0.00
0.00%
RGLS
1.45
+0.05
+3.57%
RMD
70.94
+0.2
+0.28%
SPHS
2.6
-0.01
-0.38%
SRNE
1.9
+0.15
+8.57%
TROV
0.877
-0.003
-0.3070%
VICL
2.36
-0.01
-0.38%
VOLC
18
0.00
0.00%
ZGNX
10.8
+0.2
+1.89%
Home » Archive by Category

Xconomy

Larry Smarr Drives Innovation as Experimental Patient of the Future

March 8, 2017 – 9:01 pm

In the years since he basically self-diagnosed his own Crohn’s Disease (before he had symptoms), Larry Smarr has served as a pioneer in the digital transformation of medicine and as an “n of 1”…

[[Click headline to continue reading.]]

CureMatch Uses Analytics to Rank Best Options for Cancer Treatment

March 7, 2017 – 6:45 am

CureMatch, a San Diego-based healthtech startup, says today it has created a Web-based platform that uses analytic software to help doctors sort through what can be a bewildering array of cancer…

[[Click headline to continue reading.]]

Bio Roundup: Healthcare Is Hard, “Slow” FDA, Drugging RNA & More

March 3, 2017 – 3:35 am

In an address to Congress this week, President Donald Trump outlined many of his near-term goals, including an overhaul of the Affordable Care Act, also known as Obamacare, even as public opinion has…

[[Click headline to continue reading.]]

Drugmakers, Amazon Back Grail’s Big Cancer Trials With $900M

March 1, 2017 – 6:40 am

Last month, Grail publicly spread word of intentions to raise more than $1 billion in an ambitious quest to develop a blood test that can diagnose and detect cancer at its earliest stages. Today, the…

[[Click headline to continue reading.]]

Former FDA Commissioners Califf, McClellan Talk Healthcare’s Future

March 1, 2017 – 3:57 am

The top spot at the FDA remains vacant, and the change in presidential power has some healthcare observers wondering about possible changes for the regulator. One month removed from serving as FDA…

[[Click headline to continue reading.]]

Blood Pressure Drug Trial Results Lift La Jolla Pharma Shares

February 27, 2017 – 8:18 am

La Jolla Pharmaceutical’s experimental drug to treat a deadly blood pressure condition hit its main goal in a Phase 3 clinical trial, boosting the company’s stock price by more than 75 percent on…

[[Click headline to continue reading.]]

Bio Roundup: Trump Backlash, Verdine Plans, Sarepta Sale & More

February 24, 2017 – 3:30 am

A short week makes for a shorter roundup. As we’ve come to expect, however, there was no dearth of health and life-sciences news from Washington, D.C. A bipartisan group of Congress members who…

[[Click headline to continue reading.]]

Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M

February 22, 2017 – 9:24 am

PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The company,…

[[Click headline to continue reading.]]

Cidara Antifungal Flunks in Phase 2 Clinical Trial, Sinking Shares

February 21, 2017 – 9:24 am

Cidara Therapeutics is halting work on an experimental topical antifungal drug designed to treat vaginal yeast infections after the compound wasn’t better than the current standard of care in a Phase…

[[Click headline to continue reading.]]

Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More

February 17, 2017 – 5:45 am

News may be coming out of Washington, DC, at a breakneck pace, but concrete plans regarding the future of the nation’s healthcare system, the FDA, and the pharmaceutical industry have been much…

[[Click headline to continue reading.]]